Jose Baselga

José Baselga, MD, PhD., is an internationally recognized researcher and clinician focusing primarily on breast cancer. His laboratory focuses on mechanisms that limit the sensitivity to targeted therapy in solid tumors, in particular to PI3K/Akt/mTOR inhibitors and anti-HER2 agents. He has also been involved in the preclinical and clinical development of several molecularly targeted agents including trastuzumab (Herceptin®) and lapatinib (Tykerb®), and insulin-like growth factor receptor inhibitors.

Dr. Baselga is currently the Physician-in-Chief of the Memorial Sloan Kettering Cancer Center[1] and has been named President-Elect of the American Association for Cancer Research for 2014–2015.[2] He is also past President of the European Society for Medical Oncology, past President of SOLTI and a past member of the Board of Directors of the American Society of Clinical Oncology and the AACR. Dr. Baselga has received a number of awards including a Young Investigator Award (1992) and a Career Development Award from ASCO (1994), a Brystol-Myers Squibb Unrestricted Cancer Grant Award (2002-2006), Elected Member of the American Society of Clinical Investigation (2004); AACR-Rosenthal Family Foundation Award (2008); King James I Award (2008) and the Second International Award for Cancer Research from the Rosaleda Foundation (2013). Dr. Baselga was most recently inducted into the Spanish Royal Academy of Pharmacy (2014) and the Institute of Medicine of the National Academy of Sciences (2014).

Along with having published over 350 peer-reviewed articles,[3] he is a member of the Editorial Boards of Cancer Cell, Clinical Cancer Research and Annals of Oncology and the founding editor of Cancer Discovery.

Dr Baselga received his MD degree from the Autonomous University of Barcelona in 1982. He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York and subsequently stayed on as a faculty member of the Breast Medicine Service at Memorial Sloan-Kettering. From 1996 to 2010 he was the Chairman of the Medical Oncology Service and Founding Director of the recently established Vall d’Hebron Institute of Oncology (VHIO) at the Vall d'Hebron University Hospital in Barcelona. From 2010 to 2012, he was the chief of the Division of Hematology/Oncology and associate director of the MGH Cancer Center in Massachusetts.

See also

References

  1. ↑ "Memorial Sloan Kettering Announces Appointment of New Physician-in-Chief". On Cancer (Memorial Sloan Kettering Cancer Center). September 5, 2012. Retrieved December 8, 2014.
  2. ↑ "American Association for Cancer Research Elects José Baselga, MD, PhD, as President-Elect 2014–2015". The ASCO Post 5 (6). April 15, 2014. Retrieved December 8, 2014.
  3. ↑ Author search on PubMed

External links